FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125302788> ?p ?o ?g. }

• W2125302788 endingPage "167" @default.
• W2125302788 startingPage "161" @default.
• W2125302788 abstract "BACKGROUND: Venous thromboembolism (VTE) is a frequent and potentially life-threatening complication after trauma. The purpose of this study is to investigate the effectiveness of enoxaparin in preventing deep venous thrombosis (DVT) and pulmonary embolism (PE) after injury in patients who are at high risk for developing VTE. STUDY DESIGN: A prospective single-cohort observational study was initiated for seriously injured blunt trauma patients admitted to a Level I trauma center during a 7-month period. Patients were eligible for the study if time hospitalized was ≥ 72 hours, Injury Severity Score (ISS) was ≥ 9, enoxaparin was started within 24 hours after admission, and one or more of the following high risk criteria were met: age > 50 years, ISS ≥ 16, presence of a femoral vein catheter, Abbreviated Injury Score (AIS) ≥ 3 for any body region, Glasgow Coma Scale (GCS) Score ≤ 8, presence of major pelvic, femur, or tibia fracture, and presence of direct blunt mechanism venous injury. Patients with closed head injuries and nonoperatively treated solid abdominal organ injuries were also potential participants. The primary outcomes measured were thromboembolic events—either a documented lower extremity DVT by duplex color-flow doppler ultrasonography or a PE documented by rapid infusion CT pulmonary angiography or conventional pulmonary angiography. RESULTS: There were 118 patients enrolled in the study. Two patients (2%) developed DVT, one of which was proximal to the calf (95% confidence interval, 0% to 6%). Two of 12 patients (17%) with splenic injuries who received enoxaparin failed initial nonoperative management. There were no other bleeding complications, and no clinical evidence or documented episodes of PE. One patient died from multiple system organ failure. CONCLUSIONS: Enoxaparin is a practical and effective method for reducing the incidence of VTE in high risk, seriously injured patients. This study supports further investigation into the safety of enoxaparin prophylaxis in patients with closed head injuries and nonoperatively treated solid abdominal organ injuries." @default.
• W2125302788 created "2016-06-24" @default.
• W2125302788 creator A5008741320 @default.
• W2125302788 creator A5016827787 @default.
• W2125302788 creator A5049114560 @default.
• W2125302788 creator A5049306280 @default.
• W2125302788 creator A5051940594 @default.
• W2125302788 creator A5070497250 @default.
• W2125302788 creator A5078857062 @default.
• W2125302788 date "2001-02-01" @default.
• W2125302788 modified "2023-09-24" @default.
• W2125302788 title "A Potentially Expanded Role for Enoxaparin in Preventing Venous Thromboembolism in High Risk Blunt Trauma Patients" @default.
• W2125302788 cites W1963655887 @default.
• W2125302788 cites W1967561170 @default.
• W2125302788 cites W1972875444 @default.
• W2125302788 cites W1988045314 @default.
• W2125302788 cites W1996451756 @default.
• W2125302788 cites W1999023440 @default.
• W2125302788 cites W2013619744 @default.
• W2125302788 cites W2019306886 @default.
• W2125302788 cites W2025459613 @default.
• W2125302788 cites W2026240532 @default.
• W2125302788 cites W2026821241 @default.
• W2125302788 cites W2026954924 @default.
• W2125302788 cites W2033464203 @default.
• W2125302788 cites W2036407748 @default.
• W2125302788 cites W2040548093 @default.
• W2125302788 cites W2043816590 @default.
• W2125302788 cites W2050802944 @default.
• W2125302788 cites W2064032048 @default.
• W2125302788 cites W2093502182 @default.
• W2125302788 cites W2110285942 @default.
• W2125302788 cites W2137313720 @default.
• W2125302788 cites W2322068631 @default.
• W2125302788 cites W2412312127 @default.
• W2125302788 cites W2473809699 @default.
• W2125302788 cites W4211253301 @default.
• W2125302788 cites W4252608890 @default.
• W2125302788 cites W2335152594 @default.
• W2125302788 doi "https://doi.org/10.1016/s1072-7515(00)00802-4" @default.
• W2125302788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11220715" @default.
• W2125302788 hasPublicationYear "2001" @default.
• W2125302788 type Work @default.
• W2125302788 sameAs 2125302788 @default.
• W2125302788 citedByCount "77" @default.
• W2125302788 countsByYear W21253027882012 @default.
• W2125302788 countsByYear W21253027882013 @default.
• W2125302788 countsByYear W21253027882014 @default.
• W2125302788 countsByYear W21253027882015 @default.
• W2125302788 countsByYear W21253027882016 @default.
• W2125302788 countsByYear W21253027882017 @default.
• W2125302788 countsByYear W21253027882018 @default.
• W2125302788 countsByYear W21253027882019 @default.
• W2125302788 countsByYear W21253027882020 @default.
• W2125302788 countsByYear W21253027882021 @default.
• W2125302788 countsByYear W21253027882022 @default.
• W2125302788 countsByYear W21253027882023 @default.
• W2125302788 crossrefType "journal-article" @default.
• W2125302788 hasAuthorship W2125302788A5008741320 @default.
• W2125302788 hasAuthorship W2125302788A5016827787 @default.
• W2125302788 hasAuthorship W2125302788A5049114560 @default.
• W2125302788 hasAuthorship W2125302788A5049306280 @default.
• W2125302788 hasAuthorship W2125302788A5051940594 @default.
• W2125302788 hasAuthorship W2125302788A5070497250 @default.
• W2125302788 hasAuthorship W2125302788A5078857062 @default.
• W2125302788 hasConcept C141071460 @default.
• W2125302788 hasConcept C167135981 @default.
• W2125302788 hasConcept C17624336 @default.
• W2125302788 hasConcept C188816634 @default.
• W2125302788 hasConcept C190385971 @default.
• W2125302788 hasConcept C194828623 @default.
• W2125302788 hasConcept C2776265017 @default.
• W2125302788 hasConcept C2776567890 @default.
• W2125302788 hasConcept C2777521253 @default.
• W2125302788 hasConcept C2780011451 @default.
• W2125302788 hasConcept C2780110798 @default.
• W2125302788 hasConcept C2780868729 @default.
• W2125302788 hasConcept C3017944768 @default.
• W2125302788 hasConcept C71924100 @default.
• W2125302788 hasConcept C85004164 @default.
• W2125302788 hasConceptScore W2125302788C141071460 @default.
• W2125302788 hasConceptScore W2125302788C167135981 @default.
• W2125302788 hasConceptScore W2125302788C17624336 @default.
• W2125302788 hasConceptScore W2125302788C188816634 @default.
• W2125302788 hasConceptScore W2125302788C190385971 @default.
• W2125302788 hasConceptScore W2125302788C194828623 @default.
• W2125302788 hasConceptScore W2125302788C2776265017 @default.
• W2125302788 hasConceptScore W2125302788C2776567890 @default.
• W2125302788 hasConceptScore W2125302788C2777521253 @default.
• W2125302788 hasConceptScore W2125302788C2780011451 @default.
• W2125302788 hasConceptScore W2125302788C2780110798 @default.
• W2125302788 hasConceptScore W2125302788C2780868729 @default.
• W2125302788 hasConceptScore W2125302788C3017944768 @default.
• W2125302788 hasConceptScore W2125302788C71924100 @default.
• W2125302788 hasConceptScore W2125302788C85004164 @default.
• W2125302788 hasIssue "2" @default.
• W2125302788 hasLocation W21253027881 @default.
• W2125302788 hasLocation W21253027882 @default.

• next